Session » Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III
-
Abstract Number: 1486
Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis
-
Abstract Number: 1487
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
-
Abstract Number: 1488
Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study
-
Abstract Number: 1489
Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis
-
Abstract Number: 1490
High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis
-
Abstract Number: 1491
Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance
-
Abstract Number: 1493
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
-
Abstract Number: 1494
Determinants of Clinically Important Worsening in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort over 5 Years
-
Abstract Number: 1495
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
-
Abstract Number: 1496
Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?
-
Abstract Number: 1497
How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
-
Abstract Number: 1498
The Association Between Sonographic Enthesitis with Sonographic Synovitis and Tenosynovitis in Psoriatic Arthritis
-
Abstract Number: 1499
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
-
Abstract Number: 1500
Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry
-
Abstract Number: 1501
Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)
-
Abstract Number: 1502
Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams
-
Abstract Number: 1504
Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement
-
Abstract Number: 1505
Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics
-
Abstract Number: 1506
Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study
-
Abstract Number: 1507
Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Outcome Measures in Psoriatic Arthritis
-
Abstract Number: 1508
Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
-
Abstract Number: 1510
Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries
-
Abstract Number: 1511
Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis
-
Abstract Number: 1512
What Is the Best Referral Strategy for Axial Spondyloarthritis? A Prospective Multicenter Study of 515 Patients with Suspicious Chronic Low Back Pain
-
Abstract Number: 1514
Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study